Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Disclaimer: This product is intended for Laboratory Research Use Only
Retatrutide is an experimental triple-agonist weight-loss and diabetes drug developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors
It also deacetylates FOXO3a and p53, thereby suppressing apoptosis and improving oocyte survival (82, 83)
The green dashed line indicates the predicted cleavage site (CS)
Each 10,000 USP units vial contains: chorionic gonadotropin 10,000 USP Units, Dibasic Sodium Phosphate 16 mg, Mannitol 100 mg, and Monobasic Sodium Phosphate 4 mg
(2009) Regulation of glutathione synthesis
US$ 23.90
US$ 29.85
US$ 24.49
US$ 25.87
US$ 28.72
US$ 25.50
US$ 28.56
